CLINICAL TRIALS PROFILE FOR RASAGILINE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for RASAGILINE MESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Eisai Inc. | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
| NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
| NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Teva Pharmaceutical Industries | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
| NCT00203034 ↗ | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | 2000-05-01 | Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo |
| NCT00203034 ↗ | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations | Completed | Teva Pharmaceutical Industries | Phase 3 | 2000-05-01 | Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo |
| NCT00203060 ↗ | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa | Completed | Teva Neuroscience, Inc. | Phase 3 | 1997-07-01 | Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa. |
| NCT00203125 ↗ | A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study. | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | 2000-10-01 | This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RASAGILINE MESYLATE
Condition Name
Clinical Trial Locations for RASAGILINE MESYLATE
Trials by Country
Clinical Trial Progress for RASAGILINE MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for RASAGILINE MESYLATE
Sponsor Name
